Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates

Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates

Aim. To assess the additional effect of ticagrelor as part of dual antiplatelet therapy (DAPT) compared with DAPT with clopidogrel and acetylsalicylic acid (ASA) monotherapy on the achievement of goals of federal project on the prevention of cardiovascular diseases: “reduction of cardiovascular mort...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Zhuravleva, F. N. Paleev, S. K. Zyryanov, A. N. Yakovlev, T. V. Marin, Yu. V. Gagarina
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-12-01
Series:	Российский кардиологический журнал
Subjects:	ticagrelor secondary prevention of cardiovascular disease targets cardiovascular mortality mortality from myocardial infarction federal project on the prevention of cardiovascular diseases
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4223
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program
by: M. V. Zhuravleva, et al.
Published: (2020-06-01)

Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Contribution of ticagrelor therapy in patients with acute coronary syndrome and patients with myocardial infarction to the achievement of State Program "Health Development" target in Russia as a whole and Russian regions in 2023-2025
by: M. V. Zhuravleva, et al.
Published: (2024-02-01)

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)

INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION
by: E. V. Tavlueva, et al.
Published: (2017-11-01)

Diseases of the circulatory system: health status and perspectives for changes
by: V. I. Klimenko, et al.
Published: (2014-02-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT
by: N. В. Perepech, et al.
Published: (2018-05-01)

The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
by: M. V. Zhuravleva, et al.
Published: (2022-03-01)

The Evolving Landscape of Cardiovascular Disease Prevention
by: Miguel Cainzos-Achirica, et al.
Published: (2021-09-01)

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Tea and coffee consumption and the 15-Year risk of cardiovascular events: the Isfahan cohort study (ICS)
by: Raza Amani-Beni, et al.
Published: (2025-02-01)

Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
by: T. N. Novikova
Published: (2020-09-01)

Natural dynamics of hypertriglyceridemia: incidence, regression, mortality from cardiovascular diseases and all causes (according to the results of a 17-years prospective study)
by: I. V. Dolgalyov, et al.
Published: (2011-12-01)

Risk stratification in non-ST-elevation myocardial infarction: evaluating the predictive accuracy of various risk scores in an Indian population
by: Ruchi Sharma, et al.
Published: (2025-07-01)

Changes of male and female cardiovascular mortality in the Russian Federation over 2013-2022
by: V. Yu. Semenov, et al.
Published: (2025-07-01)

Cardiovascular Outcomes of Early LDL-C Goal Achievement in Patients with Very-High-Risk ASCVD
by: Ah-Ram Kim, et al.
Published: (2025-02-01)

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?
by: O. V. Averkov, et al.
Published: (2018-09-01)

ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION
by: Y. Sakata, et al.
Published: (2012-10-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Cardiovascular risk management system: prerequisites for developing, organization principles, target groups
by: E. V. Shlyakhto, et al.
Published: (2019-11-01)

MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASES ACCORDING TO THE SEA-LEVEL RELATED ALTITUDE OF A REGION
by: A. A. Dotdaeva, et al.
Published: (2014-12-01)

Cardiovascular mortality rate in Moscow and St. Petersburg in 2015 and 2018
by: S. A. Boytsov, et al.
Published: (2021-02-01)

INTERRELATION OF TRANSCUTANEOUS CORONARY INTERVENTIONS FOR ACUTE FORMS OF CORONARY HEART DISEASE AND MORTALITY PARAMETERS IN TYUMEN REGION INHABITANTS
by: V. A. Kuznetsov, et al.
Published: (2014-06-01)

Effect modification by cardiovascular and metabolic disease onset on long-term PM2.5 exposure and mortality: a nationwide cohort study
by: Hyemin Jang, et al.
Published: (2025-06-01)

JUSTIFICATION OF A SYSTEMIC APPROACH IN THE SUDDEN CARDIAC DEATH PREVENTION: A POSSIBLE SOLUTION TO THE PROBLEM OF EXCESSIVE MORTALITY IN RUSSIA (LITERATURE REVIEW) PART I. CARDIOVASCULAR ASPECTS OF EXCESSIVE MORALITY IN RUSSIA: THE STATE OF THE PROBLEM AND POTENTIAL FOR PREVENTION
by: A. S. Dimov, et al.
Published: (2013-04-01)

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2023-12-01)

WHY CARDIOVASCULAR MORTALITY IN MOSCOW IS LOWER THAN IN OTHER REGIONS OF THE RUSSIAN FEDERATION?
by: N. V. Pogosova, et al.
Published: (2015-04-01)

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
by: Ansel Shao Pin Tang, et al.
Published: (2025-07-01)

Effects of a cardioprotective nutritional program on apolipoproteins and lipids in secondary cardiovascular disease prevention
by: Aline Marcadenti, et al.
Published: (2025-03-01)

Development of a high-performing, cost-effective and inclusive Afrocentric predictive model for stroke: a meta-analysis approach
by: M Nweke, et al.
Published: (2025-07-01)

Lipoprotein(a) as an early marker of cardiovascular events in high-risk subjects: insights from the Moli-sani cohort study
by: Francesco Gianfagna, et al.
Published: (2025-07-01)

Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension
by: M. V. Zhuravleva, et al.
Published: (2025-05-01)

CORONARY HEART DISEASE IN PERSONS OLDER THAN 55 YEARS. PREVALENCE AND PROGNOSIS
by: S. A. Shalnova, et al.
Published: (2014-08-01)

The Effects of Dual Antiplatelet Therapy on the Occurrence of Recurrent Cardiovascular Events After Myocardial Infarction in Obese Patients
by: Borovyk K., et al.
Published: (2019-04-01)

Urgent prevention in cardiovascular disease
by: V. V. Ruksin
Published: (2005-04-01)

PSORIASIS AND CARDIOVASCULAR RISK. IS THERE ANY ASSOCIATION?
by: Mateusz Gabryszewski, et al.
Published: (2024-05-01)

Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the federal diabetes register of the Russian Federation (2013–2016)
by: Viktor Y. Kalashnikov, et al.
Published: (2019-06-01)

Prevalence of hypomagnesemia and its association with clinical outcomes in patients with acute coronary syndromes
by: Munir Ahmad, et al.
Published: (2025-05-01)

Stillbirth increase long-term health risks of diabetes, CVD, CVD mortality, and all-cause mortality
by: Yi Shen, et al.
Published: (2025-07-01)